[go: up one dir, main page]

WO2003008380A1 - Carboxylic acid derivatives - Google Patents

Carboxylic acid derivatives Download PDF

Info

Publication number
WO2003008380A1
WO2003008380A1 PCT/JP2002/007250 JP0207250W WO03008380A1 WO 2003008380 A1 WO2003008380 A1 WO 2003008380A1 JP 0207250 W JP0207250 W JP 0207250W WO 03008380 A1 WO03008380 A1 WO 03008380A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid derivatives
compounds
derivatives
gpia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007250
Other languages
French (fr)
Japanese (ja)
Inventor
Masaru Takayanagi
Naoyuki Fukuchi
Masayuki Sugiki
Fumie Futaki
Shunji Takehana
Yuki Kajigaya
Yayoi Takamatsu
Munetaka Tokumasu
Kaoru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of WO2003008380A1 publication Critical patent/WO2003008380A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The compounds represented by the following formulae, which have α2β1 integrin inhibitory activity (inhibition of bonding between GPIa/IIa and collagen), or analogues thereof; and a remedial or preventive agent for various diseases which contains any of the compounds and derivatives.
PCT/JP2002/007250 2001-07-18 2002-07-17 Carboxylic acid derivatives Ceased WO2003008380A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-218507 2001-07-18
JP2001218507 2001-07-18
JP2001-351077 2001-11-16
JP2001351077A JP2005022976A (en) 2001-07-18 2001-11-16 Carboxylic acid derivative

Publications (1)

Publication Number Publication Date
WO2003008380A1 true WO2003008380A1 (en) 2003-01-30

Family

ID=26618950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007250 Ceased WO2003008380A1 (en) 2001-07-18 2002-07-17 Carboxylic acid derivatives

Country Status (2)

Country Link
JP (1) JP2005022976A (en)
WO (1) WO2003008380A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034035A1 (en) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Sulphonamide derivatives
JP2007536355A (en) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー LXR receptor modulator
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
CN102234313A (en) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 Method for synthesizing pidotimod
WO2012038942A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (en) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd Novel compound for measuring plasma kallikrein
JPH01117900A (en) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd Tripeptides and antiplasmine agent containing same
JPH0242047A (en) * 1988-05-27 1990-02-13 Pfizer Inc Cycloalkyl-substituted glutaramide diuretics
JPH02275886A (en) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd Cephalosporin compound and its production
JPH05500954A (en) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Antithrombotic peptides and pseudopeptides
JPH07501788A (en) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド Benzene sulfonamide derivatives as herbicides
JPH08505860A (en) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト Substituted amino compound, method for producing the same and method of using the same as an inhibitor of platelet aggregation
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006436A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999043709A2 (en) * 1998-02-27 1999-09-02 The Regents Of The University Of California Melanocortin receptor antagonists and modulations of melanocortin receptor activity
WO2000043415A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (en) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd Novel compound for measuring plasma kallikrein
JPH01117900A (en) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd Tripeptides and antiplasmine agent containing same
JPH0242047A (en) * 1988-05-27 1990-02-13 Pfizer Inc Cycloalkyl-substituted glutaramide diuretics
JPH02275886A (en) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd Cephalosporin compound and its production
JPH05500954A (en) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Antithrombotic peptides and pseudopeptides
JPH07501788A (en) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド Benzene sulfonamide derivatives as herbicides
JPH08505860A (en) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト Substituted amino compound, method for producing the same and method of using the same as an inhibitor of platelet aggregation
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006436A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999043709A2 (en) * 1998-02-27 1999-09-02 The Regents Of The University Of California Melanocortin receptor antagonists and modulations of melanocortin receptor activity
WO2000043415A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAERTNER H. ET AL.: "Peptide synthesis catalyzed by modified .alpha.-chymotrypsin in low-water organic media", J. ORG. CHEM., vol. 56, no. 9, 1991, pages 3149 - 3153, XP001009792 *
HAGIWARA DAIJIRO ET AL.: "Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N.alpha.-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists", J. MED. CHEM., vol. 36, no. 16, 1993, pages 2266 - 2278, XP002006315 *
HELLIO FLORENCE, GUEGUEN PAUL, MORGAT JEAN LOUIS: "Peptide enzymic microsynthesis, using carboxypeptidase Y as the catalyst: application to stepwise synthesis of Leu-enkephalin", BIOCHIMIE, vol. 70, no. 6, 1988, pages 791 - 802, XP002956674 *
OKA TATSUSHI, MORIHARA KAZUYUKI: "Trypsin as a catalyst for peptide synthesis", J. BIOCHEM., vol. 82, no. 4, 1977, TOKYO, pages 1055 - 1062, XP001011246 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
JP2007536355A (en) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー LXR receptor modulator
JP4892475B2 (en) * 2004-05-07 2012-03-07 ラボラトワール フルニエ エス・アー LXR receptor modulator
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
US8258159B2 (en) 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
WO2007034035A1 (en) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2012038942A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN102234313A (en) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 Method for synthesizing pidotimod
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US12053462B2 (en) 2018-10-30 2024-08-06 Gilead Sciences, Inc. Quinoline derivatives
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12252481B2 (en) 2021-07-09 2025-03-18 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
JP2005022976A (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2003008380A1 (en) Carboxylic acid derivatives
WO2002098869A3 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
EP1889842A4 (en) Heterocyclic compound
MXPA04004674A (en) Cannabinoid receptor ligands.
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
EP1704856A4 (en) Hsp90 family protein inhibitor
NO20032233L (en) Synergistic compounds which include a renin inhibitor for cardiovascular diseases
GB0111523D0 (en) Chemical compounds
MXPA06000013A (en) Therapeutic agent for soft tissue sarcoma.
AU2002363746A1 (en) Inventory early warning agent with correction by error correlation calculation
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004085385A3 (en) Cannabinoid receptor ligands
WO2003000220A3 (en) Use of 1,2-decandiol for combating germs causing body odour
CL2008003324A1 (en) Liquid immediate release pharmaceutical formulation comprising an acid addition salt of a substituted azetidine derivative compound and a pharmaceutically acceptable diluent or carrier useful for the treatment or prevention of thrombosis.
WO2004014893A3 (en) Antimicrobial aza-bicyclic derivates, their compositions and uses
WO2003082205A3 (en) Compounds and methods
WO2002076935A8 (en) Novel a-lipoic acid derivative and use thereof
WO2002080899A1 (en) Remedial agent for digestive disease
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
CA2468039A1 (en) Novel peptide having angiotensin converting enzyme inhibitory effect
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
NO20043211L (en) Imidazo [1,2-a] pyridine derivative
WO2005042021A3 (en) Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP